Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas.
Audrey Laroche-ClaryCoralie JosensiMarie-Alix DerieppeSarah BelhommeVéronique VendrelyRaul E PerretElaine B CadoganAntoine ItalianoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
DNA-PK inhibition deserves clinical investigation to improve response to current therapies in patients with sarcoma.